{"prompt": "['MK-7902', 'PAGE 33', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Based on prior literature (Osoba D et al., 1998; King et al., 1996, Marringwa et al., 2011),', 'point or greater worsening from baseline for each scale represents a minimally important', 'difference (MID) that represents a clinically relevant deterioration. TTD in the individual scores', 'specified above is defined as the time to first onset of >>10 (out of 100) point deterioration from', 'baseline in a given scale/subscale/item and confirmed by a second adjacent >10 point', 'deterioration from baseline. TTD in the composite endpoint is defined as the time to first onset of', 'a >10 point deterioration (i.e., increase in score) from baseline in any one of the 3 lung cancer', 'symptom scale items (EORTC-QLQ-C30 [dyspnea] and EORTC-QLQ-LC13 [cough and chest', 'pain]) with confirmation by the subsequent visit of a >10 point deterioration (i.e., increase in', 'score) from baseline in the same scale as the first onset. Changes from baseline in EORTC QLQ-', 'C30 scores will also be interpreted according to recent subscale-specific guidelines, which', 'indicate that clinically meaningful differences vary by scale (Cocks et al., 2012)', '4.5. Analysis Populations', '4.5.1.', 'Efficacy Analysis Populations', 'Efficacy analysis will be carried out in the intention-to-treat (ITT) China subpopulation. This', 'population will include all Chinese participants who are randomized in the global study and all', 'participants who are randomized in the extension portion.', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary efficacy analysis population for the global', 'study.', '4.5.2.', 'Safety Analysis Populations', 'Safety analysis will be carried out in the All Patients as Treated (APaT) China subpopulation, i.e.,', 'all randomized Chinese participants (in the global study and extension portion) who received at', 'least 1 dose of study treatment.', 'Participants from China randomized and treated in the extension portion of this study after', 'completion of the global enrollment will not be included in the primary safety analysis', 'population for the global study.', '4.5.3.', 'Patient-reported Outcome Analysis Population', 'The PRO analyses are based on the PRO Full Analysis Set (PRO FAS) China subpopulation,', 'defined as all randomized participants who have at least one PRO assessment available for the', 'specific endpoint and have received at least one dose of the study intervention. Participants will', 'be analyzed in the treatment group to which they are randomized. The PRO FAS China', 'subpopulation will include all Chinese participants (in the global study and extension portion) in', 'this population.', 'Confidential', '06Y9H6K']['MK-7902', 'PAGE 34', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary PRO analysis population for the global', 'study.', '4.5.4.', 'Pharmacokinetic Analysis Population', 'The analysis of PK data will be carried out in the population PK analysis set China subpopulation.', 'The Population PK Analysis set will include all participants who have received at least 1 dose of', 'study intervention with documented dosing history in the lenvatinib + pembrolizumab arm and', 'have measurable plasma levels of lenvatinib or serum levels of pembrolizumab. Population PK', 'Analysis Set China subpopulation will include all Chinese participants (in the global study and', 'extension portion) in this population.', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary PK analysis population for the global', 'study.', '4.6. Statistical Methods', 'Regarding the analysis for extension, no formal hypothesis testing is planned. No multiplicity', 'adjustment will be applied to the analysis for extension.', '4.6.1.', 'Statistical Methods for Efficacy Analyses', 'Analyses regarding objective response and disease progression will include all events in all', 'participants excluding events that occur in the Second Course Treatment.', '4.6.1.1.', 'Progression-free Survival', 'Analysis of PFS for extension is the same to that for the global study if applicable.', 'The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The treatment difference in PFS will be assessed by the stratified log-rank test', '(based on the stratification factors defined in Section 6.3.2 in the protocol) A stratified Cox', \"proportional hazard model with Efron's method of tie handling will be used to estimate the\", 'magnitude of the treatment difference (ie, HR) between the treatment arms. The HR and its 95%', \"CI from the stratified Cox model with Efron's method of tie handling and with a single treatment\", 'covariate will be reported. The same stratification factors used in the global study will be used', '(see section 6.3.2 in the protocol). For the Chinese subgroup analyses, the stratified method will', 'only be used if applicable. The factor of geographic region (East Asia vs. non-East Asia) will not', 'be included in the Chinese subgroup stratified analyses. An analysis using the restricted mean', 'survival time method may be conducted for PFS to account for the possible nonproportional', 'hazards effect.', 'Consistency of efficacy will be evaluated using the percentage of risk reduction preserved in the', 'Chinese subpopulation from the empirical risk reduction from the global primary efficacy analyses', '(based on point estimates). Sample size is designed to provide about 80% chance of observing the', 'point estimate of Chinese subpopulation preserves > approximately 50% of empirical risk', 'Confidential']\n\n###\n\n", "completion": "END"}